Guobang Pharma Ltd.

Equities

605507

CNE100004NS2

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
17.45 CNY -2.19% Intraday chart for Guobang Pharma Ltd. +4.74% -0.63%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. CI
Guobang Pharma Ltd. authorizes a Buyback Plan. CI
Hangzhou Shenshi Energy Conservation Technology Co.,Ltd announced that it has received CNY 200 million in funding from Zhejiang Yinxinggu Investment Co, Ltd., Guobang Pharma Ltd., Beiqi Foton Motor Co.,Ltd., China V Fund Management Co., Ltd., Gold Stone Investment Co., Ltd. and other investors. CI
Guobang Pharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guobang Pharma Ltd.(XSSC:605507) added to S&P Global BMI Index CI
Guobang Pharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guobang Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guobang Pharma Unit Passes Administrative Inspection MT
Guobang Pharma Ltd.(SHSE:605507) dropped from Shanghai Stock Exchange Health Care Sector Index CI
Guobang Pharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guobang Pharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guobang Pharma Ltd.(SHSE:605507) added to Shanghai Stock Exchange Composite Index CI
Guobang Pharma Ltd.(SHSE:605507) added to Shanghai Stock Exchange A Share Index CI
Guobang Pharma Ltd.(SHSE:605507) added to Shanghai Stock Exchange Health Care Sector Index CI
Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guobang Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
COVID-19 rattles major Chinese manufacturing province RE
Guobang Pharma Ltd. has completed an IPO in the amount of CNY 2.730131 billion. CI
Guobang Pharma Ltd. has filed an IPO. CI
Chart Guobang Pharma Ltd.
More charts
Guobang Pharma Ltd is a China-based company mainly engaged in the research and development, production, and sales of related products in the field of medicine and animal health products. The Company's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.45 CNY
Average target price
24 CNY
Spread / Average Target
+37.54%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 605507 Stock
  4. News Guobang Pharma Ltd.
  5. Guobang Pharma Unit Passes Administrative Inspection
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW